Free Trial

ORIC Pharmaceuticals 11/12/2024 Earnings Report

ORIC Pharmaceuticals logo
$8.09 -0.24 (-2.88%)
(As of 11:27 AM ET)

ORIC Pharmaceuticals EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

ORIC Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ORIC Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

A.I. Trading System Helps Some Traders Pocket $1,100 per DAY! (Ad)

What if I told you 60 seconds a day could completely change your life?

This AI-powered trading system finds high-probability option trades in less than 60 seconds a day

Click HERE to access this powerful AI Trading System

ORIC Pharmaceuticals Earnings Headlines

Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $18.29
A.I. Trading System Helps Some Traders Pocket $1,100 per DAY!

What if I told you 60 seconds a day could completely change your life?

This AI-powered trading system finds high-probability option trades in less than 60 seconds a day

Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)
See More ORIC Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ORIC Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ORIC Pharmaceuticals and other key companies, straight to your email.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals (NASDAQ:ORIC), a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

View ORIC Pharmaceuticals Profile

More Earnings Resources from MarketBeat